SUMMARY Panretinal cryotherapy (PRC) was used to treat 15 eyes with rubeosis, nine of which had established neovascular glaucoma, and seven eyes with proliferative diabetic retinopathy. The rubeosis regressed, with preservation of vision and return to normal of intraocular pressure, in all but one eye. With one exception all eyes with proliferative retinopathy also showed new vessel regression after treatment. PRC may be considered an effective alternative to retinal photocoagulation in the treatment of advanced rubeosis, early rubeotic glaucoma, and in certain circumstances proliferative diabetic retinopathy.
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Iris and retinal neovascularisation occurring secondary to an ischaemic retinopathy may cause loss of vision by a number of mechanisms. These include vitreous haemorrhage, traction retinal detachment, and neovascular glaucoma.' For many years selective retinal ablation has been shown to induce regression of both retinal and iris neovascularisation in a significant number of cases. ' The first successful application of retinal ablation in the treatment of rubeotic glaucoma was in 1960, when 3600 ablation of the retina anterior to the equator was performed with surface diathermy. 5 In 1964 cryotherapy was substituted, but when it was limited to the anterior retina many eyes lost light perception.6 Panretinal cryotherapy (PRC) applied to the retina posterior to the equator has been advocated as a method of retinal ablation, but reports to date have concluded that PRC should be withheld until rubeotic glaucoma is present because of the risk of serious complications,7 or the PRC has been combined with cyclocryotherapy.8
Our study presents the outcome of 22 eyes treated with PRC in the last six years at the Oxford Eye Hospital. The study includes nine eyes with neovascular glaucoma, six with advancing rubeosis, and seven with proliferative diabetic retinopathy.
Materials and methods
All eyes receiving PRC from one clinic between January 1979 and December 1985 were included in this study. This method of retinal ablation was Correspondence to Mr S A Vernon, Department of Ophthalmology, University Hospital, Nottingham NG7 2UH.
adopted if poor media clarity, poor pupillary dilatation, extensive retinal oedema, or patient intolerance prevented adequate photocoagulation.
Prior to PRC 10 eyes had received laser or xenon panretinal photocoagulation which had not produced neovascular regression.
Where previous photocoagulation to the posterior retina was not considered to be sufficient, or no treatment had been given in the past, xenon photocoagulation was applied around the vessel arcades and temporal to the macula immediately before PRC, with the same retrobulbar anaesthetic. In five eyes PRC was used alone (eyes 5 and 6, Table 1 and  eyes 1, 2, and 3 Table 2 ). One eye early in the series had cyclocryotherapy performed with the PRC (eye 1  Table 1 
Results

RUBEOTIC GLAUCOMA
Of the nine eyes with rubeotic glaucoma five were secondary to diabetic retinopathy (one eye had coexisting disc new vessels), three were secondary to central retinal vein occlusion (CRVO), and one followed central retinal artery occlusion (eye 9). So far all eyes have remained pain free, all showed regression of iris neovascularisation, and all but one eye had an intraocular pressure within the accepted normal range on no medication. This was the only eye to lose all light perception in this group during the follow-up period, which ranged from four months to three years. The visual acuity improved in two eyes, remained unchanged in four, and deteriorated in three (Table 1) Four months after the treatment of the left eye both eyes had normal intraocular pressures, and neither eye showed any evidence of rubeosis. The patient retained 6/60 acuity in each eye, the reduction being due to pre-existing diabetic maculopathy.
RETINAL NEOVASCULARISATION
Seven eyes were treated with PRC for disc or peripheral retinal neovascularisation. In 6 eyes this was secondary to diabetes and one eye had suffered a CRVO. Of the six diabetic eyes four were treated with PRC as vitreous haemorrhage prevented safe photocoagulation and two PRC treatments were performed because the patients could not tolerate photocoagulation. The eye with CRVO and disc new vessels had such extensive retinal oedema that adequate photocoagulation was not possible.
In the four eyes with vitreous haemorrhage, visual acuity improved by 3 lines or more in 2 eyes and by one line in one eye (Table 3) . Only one eye (eye 7, Table 3 ) lost vision, progressing via rubeotic glaucoma to no perception of light.
Case 3. A 47-year-old type 1 diabetic of 27 years' duration presented in 1980 with disc new vessels in his right eye (eye 1, Table 3 ). Argon laser and xenon arc panretinal photocoagulation failed to induce new vessel regression, and in December 1981 PRC was performed on this eye, when vitreous haemorrhage precluded further photocoagulation. Xenon panretinal photocoagulation to the left eye (eye 2, Table 3 ), performed in December 1981, was followed Our results of applying PRC to eyes with advancing rubeosis suggest that PRC should not be forgotten as an alternative method of selective retinal ablation when adequate photocoagulation cannot be performed. It appears to be effective in inducing regression of the rubeotic vessels without decreasing visual acuity when the protocol described above is followed. PRC does not feature in a major review article in 1981 on the treatment of established neovascular glaucoma.'8 Although reported complications of PRC include traction retinal detachment,7"' no evidence of retinal traction is present in eyes with rubeotic glaucoma we have treated so far. Cyclocryotherapy, advocated as a suitable treatment in the past,'9 resulted in a 6% enucleation rate, with 14% of eyes becoming phthisical and 58% losing light perception in one series.20 Valve implants, even when preceded by photocoagulation, fail to control intraocular pressure in many cases, often after repeated surgical procedures. 2' In contrast, in our series control of intraocular pressure was achieved with no additional medication in eight out of nine eyes with neovascular glaucoma. Of particular note are two eyes (eyes 3 and 7, Table 1 and almost certainly prevented the onset of glaucoma in eye 3 in Table 2 .
It has been suggested that PRC can speed the rate of clearance of vitreous haemorrhage secondary to proliferative diabetic retinopathy, and this treatment has been cited as an alternative to vitrectomy when no retinal traction exists.22 Our small series (Table 3) shows similar results, but the eye (eye 7 in Table 3 ) which progressed to rubeotic glaucoma and traction retinal detachment gives cause for concern. This eye was treated before ultrasound was available at the Oxford Eye Hospital and may have had pre-existing traction. We consider PRC should be used in the management of proliferative diabetic retinopathy with longstanding vitreous haemorrhage only when traction has been excluded by adequate retinal visualisation or ultrasound examination.
PRC is a relatively straightforward procedure to perform under local or general anaesthesia and can be quickly mastered by a surgeon with retinal experience. Regression of rubeotic vessels usually begins after a few days with complete resolution occurring after four to five weeks. Choroidal effusions are common, as is postoperative shallowing of the anterior chamber, though we have not experienced secondary angle closure to date. The intraocular pressure may also rise postoperatively, particularly in established glaucoma, and should be controlled by medical means. A transient reduction in acuity secondary to macular oedema in eyes with good vision may also occur as in case report 1, and patients should be informed that this may happen.
We believe PRC to be most effective when used in conjunction with photocoagulation at the posterior pole but have demonstrated that PRC will produce neovascular regression in certain eyes when used alone.
We recommend the use of PRC in the management of early rubeotic glaucoma, when advancing rubeosis threatens a normotensive eye, and suggest that PRC should be considered in selected cases of proliferative diabetic retinopathy where photocoagulation cannot be delivered adequately owing to media opacities.
